Amicus Therapeutics to Present at Two August Investor Conferences

Amicus Therapeutics to Present at Two August Investor Conferences

CRANBURY, N.J., Aug. 8, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics
(Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief
Executive Officer, will present a corporate overview at two upcoming
conferences in August:

  Wedbush 2013 Life Sciences Management Access Conference in New York, NY
  Date: Tuesday, August 13, 2013
  Time: 10:20 a.m. ET.

  Canaccord Genuity 33rd Annual Global Growth Conference in Boston, MA
  Date: Thursday, August 15, 2013
  Time: 10:30 a.m. ET.

Both presentations will be webcast live through the Investors section of the
Amicus Therapeutics corporate web site at, and will be archived for 90 days.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the
forefront of therapies for rare and orphan diseases. The Company is developing
novel, first-in-class treatments for a broad range of human genetic diseases,
with a focus on delivering new benefits to individuals with lysosomal storage
diseases. Amicus' lead programs include the small molecule pharmacological
chaperones migalastat HCl as a monotherapy and in combination with enzyme
replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in
combination with ERT for Pompe disease.


CONTACT: Amicus Therapeutics
         Sara Pellegrino
         (609) 662-5044
Press spacebar to pause and continue. Press esc to stop.